Inoviq Ltd (ASX: IIQ) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Inoviq Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$54.90 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
140.78 million
Earnings per share
-0.062
Dividend per share
N/A
Year To Date Return
-1.94%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Inoviq Ltd (ASX: IIQ)
Latest News
Healthcare Shares
Here's why the BARD1 (ASX:BD1) share price is crushing it today
Healthcare Shares
Why the BARD1 (ASX:BD1) share price is on the rise today
Healthcare Shares
Why is the BARD1 (ASX:BD1) share price jumping today?
Share Market News
Why the BARD1 (ASX:BD1) share price shot up 10% today
Share Market News
The BARD1 (ASX:BD1) share price eyes record highs after positive research results
Share Market News
Why the BARD1 (ASX:BD1) share price is climbing 6% today
Share Market News
These small cap ASX shares surged more than 100% in February
⏸️ ASX Shares
BARD1 (ASX:BD1) share price plummets 15% on legal proceedings
Share Market News
Why the BARD1 Life Sciences (ASX:BD1) share price is rocketing another 54% today
Share Market News
Why is the BARD1 Life Sciences (ASX:BD1) share price rocketing 78%?
❮2
IIQ ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Inoviq Ltd
INOVIQ Ltd. is a biotechnology company, which engages in the provision of medical services. Its activities include research and development of non-invasive diagnostic tests for early detection of cancer, based on certain proprietary intellectual property. The company was founded on June 30, 1983 and is headquartered in Subiaco, Australia.
IIQ Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 16 Jan 2026 | $0.39 | $0.01 | 2.60% | 112,367 | $0.39 | $0.39 | $0.38 |
| 15 Jan 2026 | $0.39 | $0.01 | 2.63% | 95,189 | $0.38 | $0.39 | $0.38 |
| 14 Jan 2026 | $0.38 | $-0.01 | -2.60% | 124,035 | $0.39 | $0.39 | $0.38 |
| 13 Jan 2026 | $0.39 | $-0.01 | -2.53% | 140,673 | $0.40 | $0.40 | $0.38 |
| 12 Jan 2026 | $0.40 | $-0.01 | -2.47% | 145,985 | $0.41 | $0.41 | $0.40 |
| 09 Jan 2026 | $0.41 | $0.01 | 2.50% | 291,418 | $0.40 | $0.41 | $0.40 |
| 08 Jan 2026 | $0.40 | $0.02 | 5.19% | 114,946 | $0.39 | $0.41 | $0.39 |
| 07 Jan 2026 | $0.39 | $-0.01 | -2.53% | 120,650 | $0.40 | $0.40 | $0.38 |
| 06 Jan 2026 | $0.40 | $0.00 | 0.00% | 160,903 | $0.40 | $0.41 | $0.39 |
| 05 Jan 2026 | $0.40 | $-0.01 | -2.50% | 130,210 | $0.40 | $0.40 | $0.39 |
| 02 Jan 2026 | $0.40 | $0.01 | 2.58% | 164,363 | $0.39 | $0.41 | $0.39 |
| 31 Dec 2025 | $0.39 | $0.02 | 5.48% | 111,654 | $0.38 | $0.39 | $0.38 |
| 30 Dec 2025 | $0.37 | $-0.01 | -2.67% | 189,976 | $0.39 | $0.39 | $0.37 |
| 29 Dec 2025 | $0.38 | $0.02 | 5.67% | 308,123 | $0.37 | $0.39 | $0.37 |
| 24 Dec 2025 | $0.35 | $0.00 | 0.00% | 16,193 | $0.35 | $0.35 | $0.35 |
| 23 Dec 2025 | $0.35 | $0.00 | 0.00% | 188,860 | $0.35 | $0.36 | $0.35 |
| 22 Dec 2025 | $0.35 | $0.01 | 2.99% | 394,676 | $0.34 | $0.35 | $0.34 |
| 19 Dec 2025 | $0.34 | $0.00 | 0.00% | 35,333 | $0.34 | $0.34 | $0.33 |
| 18 Dec 2025 | $0.34 | $-0.01 | -2.94% | 30,300 | $0.35 | $0.35 | $0.34 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 05 Nov 2025 | Philip (Phil) Powell | Buy | 85,714 | $29,999 |
Participation in share purchase plan.
|
| 05 Nov 2025 | Robert (Max) Johnston | Buy | 85,714 | $29,999 |
Participation in share purchase plan.
|
| 10 Mar 2025 | Philip (Phil) Powell | Buy | 50,000 | $17,500 |
On-market trade.
|
| 10 Mar 2025 | Robert (Max) Johnston | Buy | 37,839 | $13,243 |
On-market trade.
|
| 07 Mar 2025 | Robert (Max) Johnston | Buy | 162,161 | $56,756 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Philip (Phil) John Powell | Non-Executive Director | Jun 2019 |
Mr Powell has experience in investment banking, specializing in capital raisings, initial public offerings (IPOs), mergers and acquisitions and other successful corporate finance assignments across a diverse range of sectors including pharma, utilities, IT, financial services, food, and agriculture. He spent 10 years in audit with Arthur Andersen & Co in Melbourne, Sydney, and Los Angeles. He is the Chair of the Company's Risk Committee.
|
| Mr Peter Lynton Gunzburg | Non-Executive Director | Oct 2025 |
Mr Gunzburg brings over 40 years experience as a public company director, stockbroker, and investor. He previously served as Chairman of BARD1 Life Sciences Limited (now INOVIQ Ltd) from 2016 to 2020. Mr Gunzburg is currently Chairman of Metals X Limited (ASX: MLX) and a Non-Executive Director of London Stock Exchange listed First Tin Plc (LSE: 1SN). Mr Gunzburg has also previously been a director of Australian Stock Exchange Ltd, Eyres Reed Ltd, CIBC World Markets Australia Ltd and several other public companies.
|
| Mr Geoffrey A. Cumming | Non-Executive Director | Jul 2020 |
Dr Cumming has held senior roles in the global healthcare and biotechnology sector for 20 years. He is a member of the INOVIQ Limited Risk Committee. He has not been a director of any listed companies in the last three years other than those listed above.
|
| Mr Robert (Max) Maxwell Johnston | Non-Executive Director | Jun 2019 |
Mr Johnston held the position of President and Chief Executive Officer of Johnson & Johnson Pacific, a division of the medical, pharmaceutical and consumer healthcare company for 11 years. He has also held several industry roles as a past President of ACCORD Australasia Limited, a former Vice Chairman of the Australian Food and Grocery Council and a former member of the board of the Australian Self Medication Industry (ASMI). He is a member of the Company's Risk Committees. He has not been a director of any listed companies in the last three years other than those listed above
|
| Ms Mary Harney | Non-Executive Director | Oct 2024 |
Ms Harney is a Non-Executive Director and Chief Executive has experience of applied science research, in addition to experience in biopharmaceutical regulatory affairs and commercialization. She is the Director of specialist consulting firm Mary Harney Advisory providing leadership, governance and strategic advice across innovative industries such as health, biotech and agriculture. She currently serves as Chair of private Australian biotech Oncology One Pty Ltd, a cancer drug discovery company. She was also previously a former Chair of Microbio Limited.
|
| Dr Leearne Hinch | Chief Executive Officer | Nov 2016 |
-
|
| Mr Mark Edwards | Chief Financial OfficerCompany Secretary | Nov 2022 |
-
|
| Leearne Hinch | Chief Executive Officer |
-
|
|
| Mark Edwards | Chief Financial OfficerCompany Secretary |
-
|
|
| DR GREGORY RICE | CHIEF SCIENTIFIC OFFICER |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| The Trust Company Australia Limited <Mof A/C> | 6,487,000 | 5.81% |
| Dr Irmgard Irminger-Finger | 3,150,000 | 2.82% |
| Lawn Views Pty Ltd <Angela Williams Family A/C> | 2,676,924 | 2.40% |
| Lesamourai Pty Ltd | 2,530,495 | 2.27% |
| Moggs Creek Pty Ltd <Moggs Creek Super A/C> | 2,389,747 | 2.14% |
| Mr Peter William Rogers + Ms Alida Johanna Clark <R&C Super Fund A/C> | 1,804,436 | 1.62% |
| J P Morgan Nominees Australia Pty Limited | 1,655,031 | 1.48% |
| Supergun Pty Ltd <Bricklanding Super Fund A/C> | 1,271,000 | 1.14% |
| Trovex Pty Ltd | 1,150,000 | 1.03% |
| Mr Neil Donal Delroy <The Ndd Investment A/C> | 1,135,086 | 1.02% |
| Mr Nathan Ryan Wagner | 1,010,562 | 0.91% |
| Faraday Nominees Pty Limited <Bronte Investment A/C> | 1,000,000 | 0.90% |
| Mr Adam Garrigan | 1,000,000 | 0.90% |
| Palmers Plumbing & Hardware Pty Ltd | 962,256 | 0.86% |
| CITICORP Nominees Pty Limited | 940,051 | 0.84% |
| David Neate | 902,257 | 0.81% |
| S3 Consortium Pty Ltd | 750,000 | 0.67% |
| Jondol Pty Ltd <Jondol Estates S/F A/C> | 711,289 | 0.64% |
| Netwealth Investments Limited <Wrap Services A/C> | 670,394 | 0.60% |
| B & M Laws Super Fund Pty Ltd <B & M Laws Super Fund A/C> | 660,000 | 0.57% |
